Platinum complexes can inhibit matrix metalloproteinase activity: Platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12

被引:45
作者
Sasanelli, Rossella
Boccarelli, Angelina
Giordano, Domenico
Laforgia, Mariarita
Arnesano, Fabio
Natile, Giovanni
Cardellicchio, Cosimo
Capozzi, Maria A. M.
Coluccia, Mauro [1 ]
机构
[1] Univ Bari, Dipartimento Sci Biomed & Oncol Umana, I-70124 Bari, Italy
[2] Univ Bari, Dipartimento Farmacochim, I-70124 Bari, Italy
[3] CIRCMSB, I-70126 Bari, Italy
[4] CNR, ICCOM, Sez Bari, I-70125 Bari, Italy
[5] Univ Foggia, Dipartimento Sci Agroambientali Chim Vegetale, Fac Agr, I-71100 Foggia, Italy
关键词
D O I
10.1021/jm061435l
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Platinum complexes able to inhibit matrix metalloproteinases (MMPs) through a noncompetitive mechanism are reported for the first time in this study. [PtCl2(SMP)] and [Pt(dimethylmalonato)(SMP)], characterized by the bisphosphonate-analogue ligand diethyl[(methylsulfinyl)methyl]phosphonate (SMP), are slight inhibitors of MMP-2 (IC50 = 258 +/- 38 and 123 +/- 14 mu M, respectively) but markedly inhibit MMP-9 (IC50 = 35.5 +/- 6 and 17 +/- 4 mu M), MMP-3 (IC50 = 5.3 +/- 2.9 and 4.4 +/- 2.2 mu M), and MMP-12 (IC50 = 10.8 +/- 3 and 6.2 +/- 1.8 mu M). In contrast, cisplatin, carboplatin, and the SMP ligand are inactive, and the bisphosphonate clodronate shows a broad-spectrum inhibitory activity in the high micromolar range (mean IC50 > 200 mu M). These results, along with mechanistic investigations (DNA interaction and tumor cell growth inhibition), demonstrate that ligand modifications of platinum compounds can be exploited to target also biological substrates distinct from DNA.
引用
收藏
页码:3434 / 3441
页数:8
相关论文
共 46 条
[1]   Bioinformatic comparison of structures and homology-models of matrix metalloproteinases [J].
Andreini, C ;
Banci, L ;
Bertini, I ;
Luchinat, C ;
Rosato, A .
JOURNAL OF PROTEOME RESEARCH, 2004, 3 (01) :21-31
[2]   Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance [J].
Ang, WH ;
Khalaila, I ;
Allardyce, CS ;
Juillerat-Jeanneret, L ;
Dyson, PJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (05) :1382-1383
[3]   PSEUDYANA for NMR structure calculation of paramagnetic metalloproteins using torsion angle molecular dynamics [J].
Banci, L ;
Bertini, I ;
Cremonini, MA ;
Gori-Savellini, G ;
Luchinat, C ;
Wüthrich, K ;
Güntert, P .
JOURNAL OF BIOMOLECULAR NMR, 1998, 12 (04) :553-557
[4]   STROMELYSIN-1 - 3-DIMENSIONAL STRUCTURE OF THE INHIBITED CATALYTIC DOMAIN AND OF THE C-TRUNCATED PROENZYME [J].
BECKER, JW ;
MARCY, AI ;
ROKOSZ, LL ;
AXEL, MG ;
BURBAUM, JJ ;
FITZGERALD, PMD ;
CAMERON, PM ;
ESSER, CK ;
HAGMANN, WK ;
HERMES, JD ;
SPRINGER, JP .
PROTEIN SCIENCE, 1995, 4 (10) :1966-1976
[5]  
Boccarelli A, 1999, ANTI-CANCER DRUG DES, V14, P253
[6]  
Boissier S, 2000, CANCER RES, V60, P2949
[7]   SYNTHESIS, CHARACTERIZATION, AND DNA-BINDING PROPERTIES OF (1,2-DIAMINOETHANE)PLATINUM(II) COMPLEXES LINKED TO THE DNA INTERCALATOR ACRIDINE-ORANGE BY TRIMETHYLENE AND HEXAMETHYLENE CHAINS [J].
BOWLER, BE ;
AHMED, KJ ;
SUNDQUIST, WI ;
HOLLIS, LS ;
WHANG, EE ;
LIPPARD, SJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (04) :1299-1306
[8]   DNA adducts of antitumor trans-[PtCl2 (E-imino ether)(2)] [J].
Brabec, V ;
Vrana, O ;
Novakova, O ;
Kleinwachter, V ;
Intini, FP ;
Coluccia, M ;
Natile, G .
NUCLEIC ACIDS RESEARCH, 1996, 24 (02) :336-341
[9]   Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells [J].
Briz, O ;
Serrano, MA ;
Rebollo, N ;
Hagenbuch, B ;
Meier, PJ ;
Koepsell, H ;
Marin, JJG .
MOLECULAR PHARMACOLOGY, 2002, 61 (04) :853-860
[10]   DIFFERENTIATION OF DNA-PLATINUM COMPLEXES BY FLUORESCENCE - USE OF AN INTERCALATING DYE AS A PROBE [J].
BUTOUR, JL ;
MACQUET, JP .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1977, 78 (02) :455-463